Detection of somatostatin receptor-positive tumours using the new 99mC-tricine-HYNIC-D-Phe1-Tyr3-octreotide: First results in patients and comparison with 111In-DTPA-D-Phe1-octreotide

European Journal of Nuclear Medicine

Volumn 27, Issue 6, 2000, Pages 628-637

  Bangard, M ^b   Behe M ^a   Guhlke, S ^c   Otte, R ^c   Bender, H ^c   Maecke, H R ^a   Biersack, H J ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c NONE

Author keywords

111In DTPA D Phe1 octreotide; 99mTc tricine; HYNIC D Phe1 Tyr3 octreotide; Octreotide; Receptor scintigraphy; Somatostatin

Indexed keywords

PENTETATE INDIUM IN 111; PENTETREOTIDE; SOMATOSTATIN RECEPTOR; TRACER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; ISOTOPE LABELING; MALE; NEUROENDOCRINE TUMOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR DIAGNOSIS;

ADULT; AGED; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 0013146138     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050556     Document Type: Article

References (23)

1. 1. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-1249.
2. 2. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooji PP, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ. Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989; I: 242-244.
3. 3] octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.
4. 4. Otte A, Jermann E, Béhé M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795.
5. 90Y-SMT 487) eradicates experimental rat panceratic CA 20948 tumours. Eur J Nucl Med 1998; 25: 668-674.
6. 68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors. Horm Metab Res 1994; 26: 453-459.
7. 7. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, Macke HR. Gallium-67/gallium-68-[DFO]-octreotide - a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994; 35: 317-325.
8. 3-octreotate. A new somatostatin analog with improved target tissue uptake. Nucl Med Biol 1999; 26: 267-273.
9. 9. Vallabhajosula S, Moyer B, Lister-James J, McBride B, Lipszyc H, Lee H, Bastidas D, Dean RT. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996; 27: 1016-1022.
10. 10. Dean RT, Lister-James J, Busch LR, Moyer BR, Bloom J, Handmaker H. Tumor imaging and therapy with receptor targeted peptides. In: Limouris GS, Shukla SK, Bender H, Biersack H-J, eds. Radionuclides for oncology. Athens: Mediterran-Publishers; 1998: 57-62.
11. 11. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 1999; 115: 224-232.
12. 12. Handmaker H, Baran YM, Abernathy H. Mammoscintigraphy using technetium Tc-99m-labeled somatostatin type receptor (SSTR) binding peptide-P829. Radiology 1997; 205: 478.
13. 3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
14. 1-octreotide for the detection of somatostatin receptor positiv tumors in rats. Life Sci 1991; 49: 1593-1601.
15. 15. Thakur ML, Kolan H, Li J, Wiaderkiewicz R, Pallela VR, Duggarju R, Schally AV. Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol 1997; 24: 105-113.
16. 16. Maina T, Stolz B, Albert R, Bruns C, Koch P, Maecke H. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m. Eur J Nucl Med 1994; 21: 437-444.
17. 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre-and postconjugate labeling. Nucl Med Biol 1998; 25: 621-631.
18. 18. Béhé M. Radioaktiv markierte Peptide: Technetium Markierung von Somatostatinanaloga zur Lokalisation von neuroendokrinen Tumoren. Dissertation an der Philosophisch-Naturwissenschaftlichen Fakultät Universität, Basel, 1997.
19. 19. Maecke HR, Béhé M. New octreotide derivates labelled with technetium-99m [abstract]. J Nucl Med 1996; 37: 1144.
20. 20. Bangard M, Béhé M, Bender H, Guhlke S, Willkomm P, Risse J, Grünwald F, Maecke HR, Biersack HJ. Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results [abstract]. Eur J Nucl Med 1998; 25: 837.
21. 21. Béhé M, Maecke HR. New somatostatin analogues labeled with technetium-99m [abstract]. Eur J Nucl Med 1995; 22: 791.
22. 99mTc-labelling and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]-octreotide. Bioconj Chem 1999; 10: 431-438.
23. 23. Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999; 26: 869-876.